Compare Summit Therapeutics Inc (SMMT) vs Ermenegildo Zegna N.V. Ordinary Shares (ZGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Summit Therapeutics Inc trades at $15.02 (market cap $12.38B), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.48B). The key difference: Summit Therapeutics Inc is far larger — about 3.6× Ermenegildo Zegna N.V. Ordinary Shares's market cap, and Ermenegildo Zegna N.V. Ordinary Shares pays a 1.06% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| SMMT | ZGN | |
|---|---|---|
Market Cap | $12.38B | $3.48B |
Volume | 7,111,626 | 1,076,161 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.38 | $15.25 |
52-Week Low | $12.43 | $8.69 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $11.71B | $4.43B |
Dividend Yield | — | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.52, down 9.4% today but remains volatile following recent positive developments. The stock shows a bullish technical signal with strong moving average support and neutral oscillators. Fundamentally, the company reports no revenue and significant losses (-$1.08B net income for 2025), but recent news includes a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, driving investor optimism.
The outlook is cautiously optimistic due to strong analyst support (65% buy ratings) and a $29.33 consensus price target, representing significant upside. Key risks include ongoing cash burn, lack of current revenue, and clinical trial execution. The AstraZeneca partnership provides substantial validation and funding, but investors should monitor upcoming Q3 2026 earnings and clinical milestones for sustained momentum.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Ermenegildo Zegna N.V. Ordinary Shares
Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →
